Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Patients are receiving a first unrelated cord blood transplantation (UCBT).
• Patients start letemovir prophylaxis within 0-28 days post UCBT.
Locations
Other Locations
China
Anhui Provincial Hospital
RECRUITING
Hefei
Contact Information
Primary
Xiaoyu Zhu, ph.D
xiaoyuz@ustc.edu.cn
15255456091
Backup
Bingbing Yan
bing0415@mail.ustc.edu.cn
15993691727
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2026-05-20
Participants
Target number of participants: 60
Treatments
letermovir group
Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.
Related Therapeutic Areas
Sponsors
Leads: Anhui Provincial Hospital